22:12 , Jul 11, 2019 |  BC Innovations  |  Translation in Brief

PARP inhibitors plus senolytics: a double hit on cancer

A new approach to synthetic lethality aims to overcome resistance to PARP inhibitors by pairing them with senolytic agents, marking one of the first moves beyond DNA damage repair combinations. PARP inhibitors hinder DNA damage...
22:14 , Jun 14, 2019 |  BioCentury  |  Emerging Company Profile

Sherlock: Leveraging CRISPR, synthetic biology for diagnostics

By taking advantage of two hot technologies, Sherlock is developing a pair of molecular diagnostics that can be used alone or together to rapidly and accurately detect disease in a wide variety of applications. Sherlock...
21:26 , Jun 4, 2019 |  BC Extra  |  Politics & Policy

House committee votes to reinstate human germline gene editing ban, calls for study of allowing mitochondrial replacement

The House Appropriations Committee Tuesday voted to reinstate a prohibition on FDA review of applications to conduct research “in which a human embryo is intentionally created or modified to include a heritable genetic modification.” Several...
22:52 , Apr 26, 2019 |  BC Extra  |  Company News

European regulatory roundup: CHMP opinions and a Portola approval

EMA's CHMP recommended a basket of approvals, including Dovato dolutegravir/lamivudine, Libtayo cemiplimab and two orphan therapies. Also Friday, the European Commission granted conditional approval to Ondexxya andexanet alfa from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) to reverse...
00:27 , Apr 13, 2019 |  BioCentury  |  Tools & Techniques

ctDNA inches toward new applications

After establishing itself as a key tool for tumor profiling and patient stratification, circulating tumor DNA is now beginning to make the move into monitoring response to therapy, where it promises an early read of...
22:21 , Apr 10, 2019 |  BC Extra  |  Preclinical News

WRN identified as new synthetically lethal target

As part of an effort to exploit synthetically lethal interactions for therapeutic use, three groups independently identified a new target, a DNA helicase called WRN, in cancers with DNA microsatellite instability. Two teams -- one...
20:25 , Apr 5, 2019 |  BC Week In Review  |  Clinical News

Clovis' PARP inhibitor leads to PFS of 9.1 months in pancreatic cancer

Clovis reported at AACR that first-line maintenance treatment with Rubraca rucaparib led to a median progression-free survival of 9.1 months from the start of Rubraca therapy among 19 evaluable pancreatic cancer patients in an interim...
22:01 , Mar 15, 2019 |  BioCentury  |  Product Development

Broadening the PARP playing field

With its latest clinical win for Lynparza, AstraZeneca is leading the field in stretching the use of PARP inhibitors beyond tumors that carry BRCA mutations. The results highlight one piece of a broader strategy companies...
18:42 , Mar 8, 2019 |  BC Extra  |  Company News

TNBC gets its first targeted agent with Tecentriq approval

The approval of Roche's Tecentriq atezolizumab to treat metastatic triple-negative breast cancer gives almost half of these patients and physicians' their first agent to treat a molecularly defined subgroup of patients with this fast-progressing cancer....
22:14 , Mar 1, 2019 |  BioCentury  |  Product Development

Prostate cancer disrupted

Two imminent disruptions threaten to upend the treatment landscape for prostate cancer, changing who gets anti-androgen therapies and ushering in the first new MOAs in decades. The launch of generic abiraterone means next generation anti-androgens...